FDA Releases New Digital Template for Clinical Trials
Published Date: 5/22/2026
Notice
Summary
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Final International Digital Protocol Standard
If you run or work at a company or research group that sponsors clinical trials, the FDA issued the final M11 CeSHarP guidance on May 22, 2026. It includes three documents (a guidance, a standardized template, and a technical specification) that set a harmonized format and data fields to share clinical trial protocol information electronically and was endorsed by the ICH Assembly in November 2025.
Guidance Is Voluntary, Not Binding
The M11 CeSHarP guidance reflects the FDA's current thinking and does not create legally enforceable duties. You may use a different approach if it still meets the applicable laws and regulations.
No New Paperwork Burden Under PRA
The guidance contains no new collection of information under the Paperwork Reduction Act and refers to existing clinical trial information collections in 21 CFR part 312 that are approved under OMB control number 0910-0014.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2026-10294, Notice of Request for Revision to and Extension of an Information Collection; Standards for Privately Owned Quarantine Facilities for Ruminants
The USDA wants to update and keep collecting info from privately owned quarantine facilities that care for ruminants like cows and deer. This affects facility owners who must follow new rules to keep animals safe and healthy. Comments on these changes are open until July 21, 2026, and the update helps protect animals without adding big costs.
Next: 2026-10296, Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is asking the public and businesses to share their thoughts on how it collects information to make sure it’s useful and not too much work. They want to cut down on paperwork, especially for small businesses with fewer than 25 employees. If you want to comment, you’ve got until July 21, 2026, so don’t miss your chance to help shape smarter rules!